Release Date: 13-Jul-2024
Flap endonuclease 1 (FEN1) has emerged as a promising therapeutic target, particularly in the field of cancer research. This enzyme plays a crucial role in maintaining genomic stability by participating in various DNA repair and replication processes. The implications of targeting FEN1 have garnered significant interest due to its potential impact on cancer development and progression, as well as other indications such as viral infections.
FEN1 is a key player in the DNA damage response (DDR) pathway, which is responsible for detecting and repairing DNA lesions. Dysregulation of FEN1 activity has been implicated in various cancers, including breast, ovarian, and lung cancers. Overexpression of FEN1 has been associated with increased genomic instability, a hallmark of cancer cells, and resistance to chemotherapeutic agents.
Blacksmith Medicines' presentation of preclinical data on its lead oncology program BSM-1516, targeting FEN1, at the American Association for Cancer Research (AACR) Annual Meeting 2024 in April 2024, signifies a significant milestone in cancer therapeutics. Using their metalloenzyme fragment-based drug discovery approach, Blacksmith Medicines identified BSM-1516, a highly potent and selective inhibitor of FEN1. Notably, BSM-1516 demonstrated synergies with multiple DNA damage response (DDR) drug classes, including PARP inhibitors, PARG inhibitors, USP1 inhibitors, and ATR inhibitors, highlighting its potential for combination therapies in cancer treatment.
Preclinical studies utilizing BSM-1516 have yielded promising results, particularly in the context of HR-deficient cancer cells. In clonogenic assays, BRCA2-deficient cancer cells exhibited increased sensitivity to FEN1 inhibition compared to their BRCA2-wild-type counterparts, confirming the heightened susceptibility of HR-deficient cancer cells to FEN1 inhibition. Treatment with BSM-1516 induced cell cycle arrest, DNA damage signaling, and accumulation of chromatin-bound RPA32, a marker of single-stranded DNA, specifically in BRCA2-deficient cells. These findings underscore the potential of FEN1 inhibition as a targeted therapeutic approach for HR-deficient cancers, including those with BRCA mutations.
The inhibition of FEN1 could have far-reaching implications in cancer therapy and beyond. In the context of cancer, targeting FEN1 could sensitize cancer cells, particularly those with defective HR pathways, to DNA-damaging agents and enhance the efficacy of existing DDR-targeted therapies. Furthermore, the synergistic effects observed with BSM-1516 and other DDR inhibitors suggest potential combination therapy approaches.
The consequences of FEN1 inhibition go beyond cancer and viral infections, including autoimmune diseases and neurodegenerative disorders. Dysregulated DNA repair processes, in which FEN1 plays a crucial role, have been implicated in the pathogenesis of autoimmune diseases such as systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). In neurodegenerative disorders like Alzheimer's disease (AD) and Parkinson's disease (PD), impaired DNA repair mechanisms contribute to neuronal damage and disease progression. Targeting FEN1 may offer therapeutic benefits in these conditions by restoring DNA repair fidelity and mitigating disease pathology.
Looking ahead, the future opportunities for FEN1 inhibition as a therapeutic strategy are promising. Continued research efforts aimed at elucidating the molecular mechanisms underlying FEN1's functions and its role in disease pathogenesis will facilitate the development of novel FEN1 inhibitors with improved efficacy and safety profiles. Moreover, exploring combination therapies involving FEN1 inhibitors alongside existing treatments, such as DDR inhibitors, may enhance therapeutic outcomes and overcome resistance mechanisms in cancer and other diseases. Overall, FEN1 represents a promising therapeutic target with broad implications for improving patient care across a wide range of human diseases
For Clinical Trials Information Contact